NewbornsBONDNCT03142984
UK Baby Study Using a Baby Wash and Lotion Regimen
A study testing Cosmetic Products in people with Newborns, run by Johnson & Johnson Consumer Inc. (J&JCI) at 2 sites in United Kingdom.
Trial summary
The skin of a newborn has a sensitive skin barrier relative to an older child and an adult. Newborn's skin, for example, is extremely vulnerable to damage by environmental agents such as harsh detergents, some topical oils, and other irritant chemicals. Read more about this study
- Who is it for?
- Ages 0 to 28 daysHealthy volunteers can take part
- Conditions the study is for
- Newborns
- What is being tested?
- Cosmetic Products
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 82 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 4 Jul 2017to 4 Jun 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 28 days
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Newborn babies:
- Healthy, full-term, male or female newborns (37+ weeks gestation), with healthy normal skin
- Newborn must be within 0-14 days old at Baseline for Phase 1 and within 0-28 days old at Baseline for Phase 2
- Mothers:
- Mothers carrying singleton pregnancy of greater than or equal to (>=) 37-weeks gestation
- Mother is the one who regularly cares for the newborn. The mother must be available to attend every study visit
- Mother must be willing and able to participate in and comply with a study that requires using test products as directed on her newborn throughout study period
- Mother must be 18 years of age or older
Who cannot join
- For both Newborn babies and Mother:
- History of a confirmed coronavirus disease 2019 (COVID-19) infection in the last 30 days
- Temperature >=38.0 degree Celsius (°C) /100.4-degree Fahrenheit (°F), measured
- Use of fever reducers within the past 2 days of each onsite visit. Exception: The use of fever reducers will be acceptable in this timeframe as long as it for the appropriate indication (example teething, immunization, etc.) and not COVID related as per principal investigator (PI) assessment
- Is participating in another clinical study where the participant is currently part of an active intervention/treatment (current or planned during the study period)
- Newborn babies:
Show all 23Show fewer
- Newborn has a chromosomal abnormality or other syndromic diagnosis
- Newborn has major congenital malformations or limb defects
- Newborn is currently admitted to a neonatal unit
- Newborn with health concerns
- Newborn with known allergies or adverse reactions to common topical skincare products
- Any condition requiring use of a topical or oral over the counter (OTC) or prescription medication, which in the investigator's judgment makes the subject ineligible or places the subject at risk. Child vitamins are allowed and should be listed on the Medical Information sheet (Health and Eligibility Questionnaire) under the Concurrent Medications section
- Newborn with a known condition of asthma or any related breathing problems
- Newborn with chronic medical conditions or treatments that could interfere with the study or pose a risk to the newborn (including known immunodeficiency or lung related conditions)
- Newborn with active localized or general infections including upper respiratory infections (ear, nose, throat, fever, cough, Et cetera [etc.]).
- Have been in close contact (exposure within 6 feet/2 meters for a cumulative 15 minutes or more over a 24-hr period) with anyone who has been infected with COVID-19 within the last 14 days or the newborn is under an isolation/quarantine order (prior to enrollment and visit 6)
- Per Mother's report of her newborn's symptoms within the past 2 weeks: Unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomach aches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, fever, or chest pain/tightness
- Mother:
- Mother has a known allergies or adverse reactions to the ingredients of any of the test products
- Mother is unable to satisfactorily give informed consent for participation
- A social issue or logistical reason that, at the discretion of the direct care team, will prevent comfortable study participation by the family
- Have been in close contact (exposure within 6 feet/2 meters for a cumulative 15 minutes or more over a 24-hr period) with anyone who has been infected with COVID-19 within the last 14 days or is under an isolation/quarantine order (prior to enrollment and visit 6)
- Participants with self-reported symptoms within the past 2 weeks: Unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomach aches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, fever, or chest pain/tightness
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Saint Mary's Hospital
Manchester, Machester, M13, 9WL
The Royal Hallamshire Hospital
Sheffield, S10 2JF
About this study
Official title: A Randomized Controlled Trial of Gentle Touch/Early Massage With a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn Babies: The Barrier Optimizing Skincare for Newborn Development (BOND) Trial
The skin of a newborn has a sensitive skin barrier relative to an older child and an adult. Newborn's skin, for example, is extremely vulnerable to damage by environmental agents such as harsh detergents, some topical oils, and other irritant chemicals. Evolving perspectives on barrier dysfunction in newborn babies has led to the idea that there may be a window of opportunity in the first few months of a newborn's life to change the environmental agents that their skin is exposed to in order to maximize skin health. These environmental changes could involve the use of optimally formulated wash products and emollients, as well as the removal of all other irritant substances that could damage the skin barrier. Further research is required to identify skincare practices that are harmful and those that are positive, and to ultimately ascertain what the optimum skincare routine should be.
An important skincare strategy is to identify an appropriate regimen (use of topical emollients and wash products) that will be used to maintain healthy skin in the future. Baby massage in particular has been shown to enhance the bond between mother and newborn, highlighting that early intervention can support skin health while also being a rewarding experience.
Read more
Gentle Touch/Early Massage:
Apply the lotion with a gentle touch to communicate love to your baby and to create a special bonding moment with skin-to-skin touch. Your touch nurtures baby's social, emotional and physical development. Please take your time to apply consciously the lotion on the whole body of your baby while engaging with her/him. Your touch, light but present, will be consistent across all the face and body areas, it is delicate and soft but more than just applying the lotion.
Parents/guardians are using products to help care for their newborn's skin and there is a need to help parents/guardians identify the most appropriate products through research. This study aims to help address this need.
Read the detailed description
2 BACKGROUND 2.1 SKIN DEVELOPMENT FROM BIRTH The skin visually reaches maturity anywhere between 30 and 37 weeks of gestational age, yet neonatal and infant skin exhibits a 'sensitive' nature.1 To emphasize this, 78% of participants in one study reported a 'rash' in the first month of their newborns life.2 Its now clear that this sensitivity is related to the functioning of the skin barrier, formed by the skins uppermost layer, the stratum corneum. It takes more than 12 months following birth before the stratum corneum reaches structural maturity at a microscopic level.3 This is reflected by the reduced function of the skin barrier during this time, indicated by elevated transepidermal water loss (TEWL).4 The reduced skin barrier function exhibited during the months following birth increases the risk of irritant and allergen penetration through the skin and consequently the development of dermatological conditions.
2.2 SKIN CLEANSING For both children and adults, bathing to cleanse the skin is a hygienic necessity. The goal of hygiene is the preservation of skin health. Cleansing is essential to remove: potentially pathogenic bacteria, such as those from faeces; bodily secretions, such as faeces and saliva that contain enzymes (lipases and proteases) that breakdown the skin barrier; foods, including milk that can disturb skin homeostasis and peanuts that can cause sensitization; and other chemical irritants in the environment.1 However there is a balance to be made between cleansing the skin and preservation of its homeostatic properties such as skin barrier function and integrity.5 For instance some soaps and cleansers used to clean the skin that contain harsh detergents, such as sodium lauryl sulfate (SLS), increase skin surface pH, reduce skin hydration and alter skin barrier function.6 Nevertheless cleansers are important. Washing with water alone is ineffective at removing fat-soluble substances from skin.7 The surfactants in cleansers are required to remove these potential fat-soluble irritants. Moreover, washing with tap water alone leads to the extraction of water-soluble metabolites from the skin, including NMF, and causes mild irritation and increased skin dryness. Washing with hard water, as opposed to soft water, in particular is consistently reported to increase the risk of developing AD. A balance is therefore required between effective cleansing and the need for cleansers that are kind to the skin.8 There is now a wide range of detergents and detergent complexes available for the use in cleansing with a spectrum of effects on the skin from harsh irritant effects, such as those caused by SLS, to very mild effects comparable to washing with water alone.
The use of cleansing products compared to water alone for bathing babies has been subject to a systematic review,9 which focused on two trials. One study10 comprised of four trial arms, including washing twice weekly with a wash gel product; bathing twice weekly with water then applying a cream; bathing with wash gel and applying cream after bathing; and bathing with water only. The second study11 compared two different liquid cleansers with water for bathing infants. The results of these studies indicated no harm to skin barrier function with the tested cleaning agents, although the number of babies in each treatment arm was small.9 A large UK-based trial of a mild pH 5.5 liquid SLS-free cleanser versus water alone in bathing newborn babies for the first 28 days, conducted since this systematic review, showed essentially no differences in TEWL, hydration, skin surface pH and clinical observations.12 Skin hydration was raised in the cleanser arm at 14 days postnatal (ITT: mean wash score 49.7 (SD 9.2) vs. water 46.7 (SD 8.4), p=0.02, 95% CI -5.46 to -0.43), but was equal to those in the water group at 28 days postnatal. The evidence suggests that while some cleansers, particularly those containing SLS, can be harsh on the skin, other cleansers are available that have very mild effects on the skin, effects as least as mild as washing with water alone. The advantage of these mild cleansers is their increased cleansing efficacy and cosmetic acceptability. Given the limited number of robust clinical trials in this area there is a need to conduct further research to enable healthcare professionals and parents/carers to identify suitable and safe wash products and cleansing regimens for their babies and infants.
2.3 CURRENT GUIDANCE ON SKIN CLEANSING Current guidance on skin cleansing has been limited by the lack of available high quality evidence, leading to a number of differing guidelines.13-17 Hence, there has been confusion amongst health professionals in relation to appropriate advice.18 Guidance from the World Health Organization13 is limited to bathing a baby in warm water, at least 6 hours following birth. There is no United Kingdom NICE (National Institute for Clinical Excellence) guidance specifically about neonatal skin care. The NICE Postnatal Care Guidelines17 contains one paragraph about neonatal skin care which recommends that cleansing agents, lotions or medicated wipes should not be used; using only a mild non-perfumed soap where necessary. No evidence is cited to support this practice, and recent trials have demonstrated that the use of products can significantly reduce the development of dermatological conditions. In contrast to the NICE Postnatal Care Guideline, AWOHNN14,19 guidance is more comprehensive and specific and recommends use of a cleansing wash, with a neutral pH, that has been specifically formulated for use on babies.
Although there are guidelines available, not all are evidence based and debate still remains on best practice. The most recent guideline, produced by a panel of experts, advocates the use of wash products. Based upon this guideline the recently NHIR-funded Barrier Enhancement for Eczema Prevention (BEEP) study investigating an early skincare intervention in babies provided the following advice to participants: (1) avoid soap and bubble bath; (2) use a mild, fragrance-free synthetic cleanser designed specifically for babies; (3) avoid bath oils and additives; (4) use a mild, fragrance-free shampoo designed specifically for babies and avoid washing the suds over the baby's body; and (5) avoid using baby wipes, where possible.20 The challenge for parents is identifying 'mild' products, and so this advice currently has limited real-world value until more evidence on the effects of different products becomes available. There have been substantial advances in formulation technology of baby wash products since some of these guidelines were written highlighting the need for further research into neonatal skincare practices.10-12,21-24 2.4 INFANT SKIN MASSAGE Infant massage is a traditional practice advocated and used throughout the world to promote physical and mental development.25 Moreover it is an integral aspect of topical emollient use in newborn babies because emollient lotions and creams applied to the skin must be rubbed, or 'massaged', in. In the UK more than half of maternity/neonatal units endorse the use of massage oil as part of infant skincare.26 A number of studies into infant massage have identified potential physical and mental benefits that require validation.25 These benefits include: increased weight, length, head circumference; improved sleep; reduced episodes of crying/fussing; improved motor skills (gross and fine); enhanced personal and social behavior; and improved psychomotor development. The development of a secure attachment between parent and infant in the early years is highly protective in promoting healthy psychosocial and emotional development. Infant massage may have a role in facilitating the development of early sensitive parent - infant relationships and attunement, known precursors to the development of secure attachments27. At 2 months of age the hypothalamic-pituitary-adrenocortical system produces and regulates glucocorticoid cortisol in response to stress. Sensitive and attuned parents-infant interactions are associated with reduced cortisol excretion and thus improved affect regulation in infants28. A randomized controlled trial conducted by Gurol and Polat on infant massage in 120 newborn babies found a significant positive effect of the intervention on attachment between the mother and baby.29 The association between early secure attachment relationships, and the promotion of healthy brain development, emotional wellbeing and mental health is increasingly recognized and associated with improved outcomes for children across all domains of functioning30. Although there is significant research in the area of infant / child massage which supports positive benefits, very few studies have specifically studied the effects of massage in combination with a specific product form as a focus of the study.
Gentle Touch/Early Massage:
Apply the lotion with a gentle touch to communicate love to your baby and to create a special bonding moment with skin-to-skin touch. Your touch nurtures baby's social, emotional and physical development. Please take your time to apply consciously the lotion on the whole body of your baby while engaging with her/him. Your touch, light but present, will be consistent across all the face and body areas, it is delicate and soft but more than just applying the lotion.
Improved parent-infant interaction is currently an overlooked potential benefit of emollient use in newborn babies in most studies reported. Care is needed when selecting an emollient medium for infant massage because some topical oils have been found to damage the skin barrier.31-33 This study aims to investigate the effects of an emollient lotion specially formulated for use in newborns.
2.5 PATIENT AND PUBLIC INVOLVEMENT We have taken the views of parents with young babies into consideration when developing this study so that the findings have the greatest meaning and impact to them. In 2008 the views of 26 mothers, 20 midwives and 10 health visitors on baby bathing practices were ascertained as part of a qualitative study.18 Since then we have gathered the views of parents on baby bathing practices and clinical research on these practices as part of several clinical studies.26,31,34-37 Parents are using products to help care for their baby's skin and there is a need to help parents identify the most appropriate products through research. This study aims to help address this need.
- Conditions
- Newborns
- Being tested
- Cosmetic Products
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cosmetic ProductsOther
Phase 1:
Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)
Phase 2:
Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)
| Study group | Role | What they receive |
|---|---|---|
| Phase 1 | Experimental | An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash \& Shampoo product and Baby Lotion.
Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Receives: Other: Cosmetic Products |
| Phase 2 | Experimental | An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.
Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Receives: Other: Cosmetic Products |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in neonatal skin condition score from baseline to 3 weeks
Phase 1
Measured: 3 weeks
Change in Transepidermal Water Loss (TEWL) from baseline to 12 weeks
Phase 2
Measured: 12 weeks
Change in stratum corneum hydration (corneometer) from baseline to 12 weeks
Phase 2
Measured: 12 weeks
Number of adverse events reported related to investigations products
Phase 1
Measured: 3 weeks
Secondary outcomes (5)
Product Questionnaires
Phase 1
Measured: 3 weeks
Change in neonatal skin condition score from baseline to 12 weeks
Phase 2
Measured: 12 weeks
Change in stratum corneum surface water content (ATR-FTIR) from baseline to 12 weeks
Phase 2
Measured: 12 weeks
Change in stratum corneum lipid structure (ATR-FTIR) from baseline to 12 weeks
Phase 2
Measured: 12 weeks
Change in stratum corneum carboxylate levels (ATR-FTIR, marker of natural moisturizing factor levels and filaggrin expression) from baseline to 12 weeks
Phase 2
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2017
- Study start4 Jul 2017
- Primary completion4 Jun 2020
- Study completion4 Jun 2020
Why it stopped: The study has been on hold due to the COVID-19 pandemic. As of Mar 23, 2022, the Sponsor has decided to terminate the study for administrative reasons.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NewbornsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Sheffield
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03142984
- Sponsor's protocol ID
- CO-1610 1411 2628-SBCT
- Other IDs
- CO-161014112628-SBCT
- Acronym
- BOND
- Status last verified
- Nov 2023
- First submitted
- 2 May 2017
- Last updated
- 4 Dec 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of Gentle Touch/Early Massage With a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn Babies: The Barrier Optimizing Skincare for Newborn Development (BOND) Trial
- ClinicalTrials.gov ID
- NCT03142984
- Acronym / sponsor ID
- BOND / CO-1610 1411 2628-SBCT
- Conditions
- Newborns
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The study has been on hold due to the COVID-19 pandemic. As of Mar 23, 2022, the Sponsor has decided to terminate the study for administrative reasons.
- Enrolment
- 82 participants (actual)
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)Industry (pharma, biotech, devices)
- Collaborators
- University of Sheffield
- Study start
- 4 Jul 2017 (actual)
- Primary completion
- 4 Jun 2020 (actual)
- Study completion
- 4 Jun 2020 (actual)
- First posted
- 8 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The skin of a newborn has a sensitive skin barrier relative to an older child and an adult. Newborn's skin, for example, is extremely vulnerable to damage by environmental agents such as harsh detergents, some topical oils, and other irritant chemicals. Evolving perspectives on barrier dysfunction in newborn babies has led to the idea that there may be a window of opportunity in the first few months of a newborn's life to change the environmental agents that their skin is exposed to in order to maximize skin health. These environmental changes could involve the use of optimally formulated wash products and emollients, as well as the removal of all other irritant substances that could damage the skin barrier. Further research is required to identify skincare practices that are harmful and those that are positive, and to ultimately ascertain what the optimum skincare routine should be.
An important skincare strategy is to identify an appropriate regimen (use of topical emollients and wash products) that will be used to maintain healthy skin in the future. Baby massage in particular has been shown to enhance the bond between mother and newborn, highlighting that early intervention can support skin health while also being a rewarding experience.
Gentle Touch/Early Massage:
Apply the lotion with a gentle touch to communicate love to your baby and to create a special bonding moment with skin-to-skin touch. Your touch nurtures baby's social, emotional and physical development. Please take your time to apply consciously the lotion on the whole body of your baby while engaging with her/him. Your touch, light but present, will be consistent across all the face and body areas, it is delicate and soft but more than just applying the lotion.
Parents/guardians are using products to help care for their newborn's skin and there is a need to help parents/guardians identify the most appropriate products through research. This study aims to help address this need.
Detailed description
2 BACKGROUND 2.1 SKIN DEVELOPMENT FROM BIRTH The skin visually reaches maturity anywhere between 30 and 37 weeks of gestational age, yet neonatal and infant skin exhibits a 'sensitive' nature.1 To emphasize this, 78% of participants in one study reported a 'rash' in the first month of their newborns life.2 Its now clear that this sensitivity is related to the functioning of the skin barrier, formed by the skins uppermost layer, the stratum corneum. It takes more than 12 months following birth before the stratum corneum reaches structural maturity at a microscopic level.3 This is reflected by the reduced function of the skin barrier during this time, indicated by elevated transepidermal water loss (TEWL).4 The reduced skin barrier function exhibited during the months following birth increases the risk of irritant and allergen penetration through the skin and consequently the development of dermatological conditions.
2.2 SKIN CLEANSING For both children and adults, bathing to cleanse the skin is a hygienic necessity. The goal of hygiene is the preservation of skin health. Cleansing is essential to remove: potentially pathogenic bacteria, such as those from faeces; bodily secretions, such as faeces and saliva that contain enzymes (lipases and proteases) that breakdown the skin barrier; foods, including milk that can disturb skin homeostasis and peanuts that can cause sensitization; and other chemical irritants in the environment.1 However there is a balance to be made between cleansing the skin and preservation of its homeostatic properties such as skin barrier function and integrity.5 For instance some soaps and cleansers used to clean the skin that contain harsh detergents, such as sodium lauryl sulfate (SLS), increase skin surface pH, reduce skin hydration and alter skin barrier function.6 Nevertheless cleansers are important. Washing with water alone is ineffective at removing fat-soluble substances from skin.7 The surfactants in cleansers are required to remove these potential fat-soluble irritants. Moreover, washing with tap water alone leads to the extraction of water-soluble metabolites from the skin, including NMF, and causes mild irritation and increased skin dryness. Washing with hard water, as opposed to soft water, in particular is consistently reported to increase the risk of developing AD. A balance is therefore required between effective cleansing and the need for cleansers that are kind to the skin.8 There is now a wide range of detergents and detergent complexes available for the use in cleansing with a spectrum of effects on the skin from harsh irritant effects, such as those caused by SLS, to very mild effects comparable to washing with water alone.
The use of cleansing products compared to water alone for bathing babies has been subject to a systematic review,9 which focused on two trials. One study10 comprised of four trial arms, including washing twice weekly with a wash gel product; bathing twice weekly with water then applying a cream; bathing with wash gel and applying cream after bathing; and bathing with water only. The second study11 compared two different liquid cleansers with water for bathing infants. The results of these studies indicated no harm to skin barrier function with the tested cleaning agents, although the number of babies in each treatment arm was small.9 A large UK-based trial of a mild pH 5.5 liquid SLS-free cleanser versus water alone in bathing newborn babies for the first 28 days, conducted since this systematic review, showed essentially no differences in TEWL, hydration, skin surface pH and clinical observations.12 Skin hydration was raised in the cleanser arm at 14 days postnatal (ITT: mean wash score 49.7 (SD 9.2) vs. water 46.7 (SD 8.4), p=0.02, 95% CI -5.46 to -0.43), but was equal to those in the water group at 28 days postnatal. The evidence suggests that while some cleansers, particularly those containing SLS, can be harsh on the skin, other cleansers are available that have very mild effects on the skin, effects as least as mild as washing with water alone. The advantage of these mild cleansers is their increased cleansing efficacy and cosmetic acceptability. Given the limited number of robust clinical trials in this area there is a need to conduct further research to enable healthcare professionals and parents/carers to identify suitable and safe wash products and cleansing regimens for their babies and infants.
2.3 CURRENT GUIDANCE ON SKIN CLEANSING Current guidance on skin cleansing has been limited by the lack of available high quality evidence, leading to a number of differing guidelines.13-17 Hence, there has been confusion amongst health professionals in relation to appropriate advice.18 Guidance from the World Health Organization13 is limited to bathing a baby in warm water, at least 6 hours following birth. There is no United Kingdom NICE (National Institute for Clinical Excellence) guidance specifically about neonatal skin care. The NICE Postnatal Care Guidelines17 contains one paragraph about neonatal skin care which recommends that cleansing agents, lotions or medicated wipes should not be used; using only a mild non-perfumed soap where necessary. No evidence is cited to support this practice, and recent trials have demonstrated that the use of products can significantly reduce the development of dermatological conditions. In contrast to the NICE Postnatal Care Guideline, AWOHNN14,19 guidance is more comprehensive and specific and recommends use of a cleansing wash, with a neutral pH, that has been specifically formulated for use on babies.
Although there are guidelines available, not all are evidence based and debate still remains on best practice. The most recent guideline, produced by a panel of experts, advocates the use of wash products. Based upon this guideline the recently NHIR-funded Barrier Enhancement for Eczema Prevention (BEEP) study investigating an early skincare intervention in babies provided the following advice to participants: (1) avoid soap and bubble bath; (2) use a mild, fragrance-free synthetic cleanser designed specifically for babies; (3) avoid bath oils and additives; (4) use a mild, fragrance-free shampoo designed specifically for babies and avoid washing the suds over the baby's body; and (5) avoid using baby wipes, where possible.20 The challenge for parents is identifying 'mild' products, and so this advice currently has limited real-world value until more evidence on the effects of different products becomes available. There have been substantial advances in formulation technology of baby wash products since some of these guidelines were written highlighting the need for further research into neonatal skincare practices.10-12,21-24 2.4 INFANT SKIN MASSAGE Infant massage is a traditional practice advocated and used throughout the world to promote physical and mental development.25 Moreover it is an integral aspect of topical emollient use in newborn babies because emollient lotions and creams applied to the skin must be rubbed, or 'massaged', in. In the UK more than half of maternity/neonatal units endorse the use of massage oil as part of infant skincare.26 A number of studies into infant massage have identified potential physical and mental benefits that require validation.25 These benefits include: increased weight, length, head circumference; improved sleep; reduced episodes of crying/fussing; improved motor skills (gross and fine); enhanced personal and social behavior; and improved psychomotor development. The development of a secure attachment between parent and infant in the early years is highly protective in promoting healthy psychosocial and emotional development. Infant massage may have a role in facilitating the development of early sensitive parent - infant relationships and attunement, known precursors to the development of secure attachments27. At 2 months of age the hypothalamic-pituitary-adrenocortical system produces and regulates glucocorticoid cortisol in response to stress. Sensitive and attuned parents-infant interactions are associated with reduced cortisol excretion and thus improved affect regulation in infants28. A randomized controlled trial conducted by Gurol and Polat on infant massage in 120 newborn babies found a significant positive effect of the intervention on attachment between the mother and baby.29 The association between early secure attachment relationships, and the promotion of healthy brain development, emotional wellbeing and mental health is increasingly recognized and associated with improved outcomes for children across all domains of functioning30. Although there is significant research in the area of infant / child massage which supports positive benefits, very few studies have specifically studied the effects of massage in combination with a specific product form as a focus of the study.
Gentle Touch/Early Massage:
Apply the lotion with a gentle touch to communicate love to your baby and to create a special bonding moment with skin-to-skin touch. Your touch nurtures baby's social, emotional and physical development. Please take your time to apply consciously the lotion on the whole body of your baby while engaging with her/him. Your touch, light but present, will be consistent across all the face and body areas, it is delicate and soft but more than just applying the lotion.
Improved parent-infant interaction is currently an overlooked potential benefit of emollient use in newborn babies in most studies reported. Care is needed when selecting an emollient medium for infant massage because some topical oils have been found to damage the skin barrier.31-33 This study aims to investigate the effects of an emollient lotion specially formulated for use in newborns.
2.5 PATIENT AND PUBLIC INVOLVEMENT We have taken the views of parents with young babies into consideration when developing this study so that the findings have the greatest meaning and impact to them. In 2008 the views of 26 mothers, 20 midwives and 10 health visitors on baby bathing practices were ascertained as part of a qualitative study.18 Since then we have gathered the views of parents on baby bathing practices and clinical research on these practices as part of several clinical studies.26,31,34-37 Parents are using products to help care for their baby's skin and there is a need to help parents identify the most appropriate products through research. This study aims to help address this need.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Phase 1 | Experimental | Other: Cosmetic ProductsAn open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash \& Shampoo product and Baby Lotion. Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) |
| Phase 2 | Experimental | Other: Cosmetic ProductsAn evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage. Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) |
Who may qualify
- Ages
- 0 to 28 days
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (8 listed)
- Healthy, full-term, male or female newborns (37+ weeks gestation), with healthy normal skin
- Newborn must be within 0-14 days old at Baseline for Phase 1 and within 0-28 days old at Baseline for Phase 2
- Mothers carrying singleton pregnancy of greater than or equal to (>=) 37-weeks gestation
- Mother is the one who regularly cares for the newborn. The mother must be available to attend every study visit
- Mother must be willing and able to participate in and comply with a study that requires using test products as directed on her newborn throughout study period
Key exclusion criteria (23 listed)
- History of a confirmed coronavirus disease 2019 (COVID-19) infection in the last 30 days
- Temperature >=38.0 degree Celsius (°C) /100.4-degree Fahrenheit (°F), measured
- Use of fever reducers within the past 2 days of each onsite visit. Exception: The use of fever reducers will be acceptable in this timeframe as long as it for the appropriate indication (example teething, immunization, etc.) and not COVID related as per principal investigator (PI) assessment
- Is participating in another clinical study where the participant is currently part of an active intervention/treatment (current or planned during the study period)
- Newborn has a chromosomal abnormality or other syndromic diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cosmetic ProductsPhase 1: Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Phase 2: Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) | Other | Phase 1, Phase 2 |
Primary outcome
Change in neonatal skin condition score from baseline to 3 weeks
Time frame: 3 weeks
Phase 1
Change in Transepidermal Water Loss (TEWL) from baseline to 12 weeks
Time frame: 12 weeks
Phase 2
Change in stratum corneum hydration (corneometer) from baseline to 12 weeks
Time frame: 12 weeks
Phase 2
Number of adverse events reported related to investigations products
Time frame: 3 weeks
Phase 1
5 secondary outcomes
Product Questionnaires
Time frame: 3 weeks
Change in neonatal skin condition score from baseline to 12 weeks
Time frame: 12 weeks
Change in stratum corneum surface water content (ATR-FTIR) from baseline to 12 weeks
Time frame: 12 weeks
Change in stratum corneum lipid structure (ATR-FTIR) from baseline to 12 weeks
Time frame: 12 weeks
Change in stratum corneum carboxylate levels (ATR-FTIR, marker of natural moisturizing factor levels and filaggrin expression) from baseline to 12 weeks
Time frame: 12 weeks
Results and safety
The study was stopped early (reason given: The study has been on hold due to the COVID-19 pandemic. As of Mar 23, 2022, the Sponsor has decided to terminate the study for administrative reasons.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2023.
- A Randomized Controlled Trial of Gentle Touch/Early Massage with a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn BabiesLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Related trials for Newborns
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
Renal Failure Congenital, Congenital Renal Anomaly Nos
RecruitingPhase 1/2
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
X-linked Hypophosphatemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cosmetic Products in people with Newborns, run by Johnson & Johnson Consumer Inc. (J&JCI) at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 4 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The study has been on hold due to the COVID-19 pandemic. As of Mar 23, 2022, the Sponsor has decided to terminate the study for administrative reasons.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in neonatal skin condition score from baseline to 3 weeks (time frame: 3 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2023.